Cardiac Science and Quinton Cardiology Systems complete merger

4 September 2005

Washington, USA. Quinton Cardiology Systems, Inc. (Nasdaq:QUIN)  and Cardiac Science, Inc. (Nasdaq: DFIB), have completed their merger, resulting in a combined company called Cardiac Science Corporation (Nasdaq: CSCX). Quinton manufactures cardiology products such as electrocardiographs, stress test systems and monitors. Cardiac Science makes automatic external defibrillators (AEDs) and patient monitors.

Cardiac Science's manufacturing operations will be consolidated into Quinton's factory in Washington. Quinton acquired the business from GE Medical Systems, now called GE Healthcare Technologies, in 2003. Cardiac Science's administrative operations will also be consolidated into Quinton's headquarters in Seattle, Washington.

The merger was approved in special meetings on 31 August by the respective stockholders of both Cardiac Science and Quinton. Approximately 96% of the shares of Cardiac Science common stock cast at the Cardiac Science special meeting voted in favour of the merger proposal and approximately 97% of the shares of Quinton common stock cast at the Quinton special meeting voted in favour of the merger proposal.

The merger agreement was originally approved by the boards of directors of both companies in February 2005. “We appreciate the overwhelming support of the shareholders of both organisations,”
said Cardiac Science Corporation President and Chief Executive Officer and former Quinton CEO, John R. Hinson. “We believe the new company will have enhanced prospects for revenue growth based on our expanded product portfolio, stronger distribution capabilities in both the domestic and international markets, and the potential
to leverage combined technological expertise and manufacturing strengths. We will now turn our focus to completing our integration work during the balance of 2005 and creating value for all Cardiac Science Corporation stakeholders.”

"The merger creates a significantly larger, debt free company with excellent people, technology and products which speak well for our future prospects,” said former Cardiac Science Chairman and CEO Raymond W. Cohen, who will continue as Chairman of the
Board of the new company. “Both John Hinson and Michael Matysik, the company’s CEO and CFO, have the management expertise and leadership skills necessary to ensure we realize the potential for growth in revenue and profitability.”

For further information see:

To top


To top